Concert Pharmaceuticals Garners $37,000,000 Series C Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=99d7c5fd-86fd-429f-8441-833564ee286a&Preview=1 - Date
4/30/2008 - Company Name
Concert Pharmaceuticals - Mailing Address
99 Hayden Avenue Lexington, MA 02421 - Company Description
Concert Pharmaceuticals, a privately held pharmaceutical company, is focused on developing novel small molecule drugs for unmet medical needs. Concert utilizes its advanced methodology to rapidly create potent bioavailable drug candidates. - Website
http://www.concertpharma.com/
- Transaction Type
Venture Equity - Transaction Amount
$37,000,000 - Transaction Round
Series C - Proceeds Purposes
The Company intends to use the proceeds to further advance its deuterium chemistry platform and product pipeline. - M&A Terms
- Venture Investor
Undisclosed - Venture Investor
Adage Capital Management - Venture Investor
Three Arch Partners - Venture Investor
TVM Capital - Venture Investor
Skyline Ventures - Venture Investor
Flagship Ventures - Venture Investor
Brookside Capital - Venture Investor
Greylock Partners - Venture Investor
New Leaf Venture Partners - Venture Investor
QVT Fund LP
